hepacult GmbH

Company

    • Company type:
      • Manufacturer
      • Research & Development
      • Service Provider
    • Year founded:
    • 2002
    • Employees (at the site):
    • 6
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Toxicology, Analytical and Clinical Research, Tissue Engineering / Cell Culture, Drug Development, Analytical Chemistry

    • Core competencies:
    • hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

    • Language skills:
    • English
      German
    • Key Tech / section:
      • Biotechnology: Preclinical development
      • Biotechnology: Tissue engineering and regenerative medicine
      • Medical Technology: Implants, biomaterials, tissue engineering
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
      • Austria
      • Germany
      • Switzerland
      • United Kingdom
    • Cooperation offers:
    • not available
    • Contact person:
    • Liming Ge (Mr.)
      - Management
      - Sales / marketing